ALGORX AND CORGENTECH ANNOUNCE DATA FROM SECOND OF TWO TRIALS OF ALGRX 3268

AlgoRx Pharmaceuticals and Corgentech have announced positive data from the second of two Phase III trials of ALGRX 3268 -- a fast-acting local anesthetic administered into the skin by powder injection and aimed at reducing pain associated with venipunctures and intravenous line placements. The primary endpoint of the 535-pediatric patient trial was achieved showing that treatment with ALGRX 3268 demonstrated statistically significantly less pain compared with the placebo group. ALGRX 3268 was well-tolerated and demonstrated no significant safety issues.

The trial was conducted at nine centers in the U.S. in patients 3 to 18 years of age. A total of 535 patients were administered a placebo (266 patients) or the local anesthetic, ALGRX 3268 (269 patients) one to three minutes before having procedures that required either venipuncture or intravenous line placement.

The primary endpoint of the trial was achieved, showing that treatment with ALGRX 3268 demonstrated significantly less pain compared with the placebo group. ALGRX 3268 was well-tolerated and demonstrated no significant safety issues.